441 related articles for article (PubMed ID: 12952752)
1. A review of thalidomide's history and current dermatological applications.
Perri AJ; Hsu S
Dermatol Online J; 2003 Aug; 9(3):5. PubMed ID: 12952752
[TBL] [Abstract][Full Text] [Related]
2. Innovative uses of thalidomide.
Chen M; Doherty SD; Hsu S
Dermatol Clin; 2010 Jul; 28(3):577-86. PubMed ID: 20510766
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide: an experience in therapeutic outcome and adverse reactions.
Sharma NL; Sharma VC; Mahajan VK; Shanker V; Ranjan N; Gupta M
J Dermatolog Treat; 2007; 18(6):335-40. PubMed ID: 17852637
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide: dermatological indications, mechanisms of action and side-effects.
Wu JJ; Huang DB; Pang KR; Hsu S; Tyring SK
Br J Dermatol; 2005 Aug; 153(2):254-73. PubMed ID: 16086735
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide and its dermatologic uses.
Paghdal KV; Schwartz R
Acta Dermatovenerol Croat; 2007; 15(1):39-44. PubMed ID: 17433179
[TBL] [Abstract][Full Text] [Related]
6. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
Fabi SG; Hill C; Witherspoon JN; Boone SL; West DP
J Drugs Dermatol; 2009 Aug; 8(8):765-9. PubMed ID: 19663116
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide in leprosy and some dermatological conditions--a review.
Parikh DA; Maniar JK; Ganapati R
Indian J Lepr; 1985; 57(4):862-7. PubMed ID: 3915010
[No Abstract] [Full Text] [Related]
8. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood.
Shannon EJ; Ejigu M; Haile-Mariam HS; Berhan TY; Tasesse G
Lepr Rev; 1992 Mar; 63(1):5-11. PubMed ID: 1569817
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide: a re-look.
Grover JK; Vats V; Gopalakrishna R; Ramam M
Natl Med J India; 2000; 13(3):132-41. PubMed ID: 11558112
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide and its dermatologic uses.
Moraes M; Russo G
Am J Med Sci; 2001 May; 321(5):321-6. PubMed ID: 11370795
[TBL] [Abstract][Full Text] [Related]
11. [Should thalidomide be rehabilitated?].
Belaube P; Garcin G; Marchand JP; Privat Y
Sem Hop; 1983 Dec; 59(45):3101-4. PubMed ID: 6320398
[TBL] [Abstract][Full Text] [Related]
12. The role of thalidomide in the management of erythema nodosum leprosum.
Walker SL; Waters MF; Lockwood DN
Lepr Rev; 2007 Sep; 78(3):197-215. PubMed ID: 18035771
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide--effect on T cell subsets as a possible mechanism of action.
Moncada B; Baranda ML; González-Amaro R; Urbina R; Loredo CE
Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):201-5. PubMed ID: 3874920
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and its impact in dermatology.
Stirling DI
Semin Cutan Med Surg; 1998 Dec; 17(4):231-42. PubMed ID: 9859910
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide: current and potential clinical applications.
Calabrese L; Fleischer AB
Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide levels in patients with erythema nodosum leprosum.
Vieira JL; Valente Mdo S
Ther Drug Monit; 2009 Oct; 31(5):602-3. PubMed ID: 19704404
[TBL] [Abstract][Full Text] [Related]
17. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
de Carsalade GY; Achirafi A; Flageul B
Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide: new preparation. For well-defined indications.
Prescrire Int; 1998 Oct; 7(37):131-4. PubMed ID: 10848043
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide in erythema nodosum leprosum (ENL).
Bourdillon C
Lepr Rev; 1988 Jun; 59(2):184-5. PubMed ID: 3246930
[No Abstract] [Full Text] [Related]
20. A case series of 48 patients treated with thalidomide.
Doherty SD; Hsu S
J Drugs Dermatol; 2008 Aug; 7(8):769-73. PubMed ID: 18720694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
